Premium
Decursin inhibits the growth of HepG2 hepatocellular carcinoma cells via Hippo/YAP signaling pathway
Author(s) -
Li Jianchun,
Wang Honglian,
Wang Lu,
Tan Ruizhi,
Zhu Menglian,
Zhong Xia,
Zhang Yuwei,
Chen Bo,
Wang Li
Publication year - 2018
Publication title -
phytotherapy research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.019
H-Index - 129
eISSN - 1099-1573
pISSN - 0951-418X
DOI - 10.1002/ptr.6184
Subject(s) - apoptosis , hepatocellular carcinoma , cell growth , hippo signaling pathway , cancer research , in vivo , signal transduction , medicine , pharmacology , liver cancer , cell cycle , cell , microbiology and biotechnology , chemistry , endocrinology , biology , biochemistry
Targeted therapy has a pivotal role for the treatment of liver cancer. The aim of this current study was to examine the effects of decursin on the growth of HepG2 cells and the underlying mechanisms. Our present study showed that treatment of HepG2 cells with decursin significantly inhibited the growth of HepG2 cells by suppressing cell proliferation, cell cycle arresting, and promoting apoptosis in a dose‐ and time‐dependent manner. Most significantly, administration of decursin dramatically impeded in vivo tumor growth in nude mice. Mechanically, it is noteworthy that decursin treatment provoked degradation of YAP by upregulating the expression of phosphorylated LATS1 and βTRCP. Moreover, apoptosis caused by decursin could be reversed by a selective MST1/2 inhibitor, XMU‐MP‐1, suggesting that decursin may function through Hippo/YAP signaling. This study has identified that decursin is a potential agent for HCC therapy, and further research should be undertaken to facilitate its therapeutic application.